Glassman Robert sold $332K of PHVS

Glassman Robert sold 8,667 shares of Pharvaris N.V. (PHVS) at $38.27 ($0.33M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glassman Robert
Published Sep 17, 2026, 1:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Bearish
medium confidence
Mentioned
$PHVS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSBearishLow
01

Why it matters

A director's sale may be viewed as a bearish cue, but the size is modest.

02

Market read

New insider sale adds modest negative sentiment for PHVS.

03

What to watch

The 10b5‑1 plan pre‑arranged nature reduces interpretive weight.

Relevance 3/10Novelty 4/10Timing: filed Sep 17 after market close

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$PHVSBearishMedium confidence
Context

Director Robert Glassman sold 8,667 shares for $331,716 via a 10b5‑1 plan, reducing his stake to 10,500 shares.

Expected impact

Modest short‑term downside pressure, likely <2% move.

Evidence & confidence

A $332K sale by a director is material for a micro‑cap biotech, but the amount is modest relative to market cap.

Market effects

May raise scrutiny on insider activity within biotech sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Insider sale could be routine liquidity need, not a negative signal.

Key entities

  • Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Robert Glassman

    Insider who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.